Why is Medicamen Biotec falling/rising?

As of 14-Jul, Medicamen Biotech Ltd's stock price is currently at Rs 383.85, reflecting a decline of Rs 9.15 or 2.33%. The stock has underperformed its sector by 1.54% today and is trading close to its 52-week low, just 3.46% away from Rs 377. The stock has shown a significant decline over various periods, with a 1-week return of -4.69%, a 1-month return of -7.09%, and a year-to-date return of -24.62%. Key financial metrics indicate poor performance, with the company experiencing a -16.39% annual growth rate in operating profit over the last five years, and a return on capital employed (ROCE) at a low of 5.30%. Additionally, the stock's cash and cash equivalents are at their lowest, and net sales have also decreased, contributing to the negative sentiment surrounding the stock.
In the broader market context, Medicamen Biotech's performance has been consistently weaker than the benchmark, with the Sensex showing a positive return of 5.27% year-to-date, while Medicamen has declined significantly. The stock's performance over the last three years has been particularly poor, with a return of -42.43% compared to the Sensex's 53.99% gain. This consistent underperformance, coupled with falling investor participation and liquidity concerns, has led to a negative outlook for the stock. The company's expensive valuation relative to its peers, despite trading at a discount, further exacerbates the situation, indicating a lack of investor confidence in its future growth potential.